Your browser doesn't support javascript.
loading
Patient Perceptions of Exertion and Dyspnea With Interleukin-1 Blockade in Patients With Recently Decompensated Systolic Heart Failure.
Mihalick, Virginia; Wohlford, George; Talasaz, Azita H; Ho, Ai-Chen Jane; Kim, Francine; Canada, Justin M; Carbone, Salvatore; Kadariya, Dinesh; Billingsley, Hayley; Trankle, Cory; Del Buono, Marco Giuseppe; Moroni, Francesco; Arena, Ross; Abbate, Antonio; Van Tassell, Benjamin.
Afiliação
  • Mihalick V; VCU Pauley Heart Center; Department of Pharmacotherapy & Outcomes Sciences.
  • Wohlford G; Department of Pharmacotherapy & Outcomes Sciences.
  • Talasaz AH; Department of Pharmacotherapy & Outcomes Sciences.
  • Ho AJ; Department of Pharmacotherapy & Outcomes Sciences.
  • Kim F; Department of Pharmacotherapy & Outcomes Sciences.
  • Canada JM; VCU Pauley Heart Center.
  • Carbone S; VCU Pauley Heart Center; Department of Kinesiology & Health Sciences, College of Humanities & Sciences, Virginia Commonwealth University, Richmond, Virginia.
  • Kadariya D; VCU Pauley Heart Center.
  • Billingsley H; Department of Kinesiology & Health Sciences, College of Humanities & Sciences, Virginia Commonwealth University, Richmond, Virginia.
  • Trankle C; VCU Pauley Heart Center.
  • Del Buono MG; VCU Pauley Heart Center.
  • Moroni F; VCU Pauley Heart Center.
  • Arena R; Department of Physical Therapy, College of Applied Health Sciences, University of Illinois at Chicago, Chicago, Illinois.
  • Abbate A; VCU Pauley Heart Center.
  • Van Tassell B; Department of Pharmacotherapy & Outcomes Sciences. Electronic address: bvantassell@vcu.edu.
Am J Cardiol ; 174: 61-67, 2022 07 01.
Article em En | MEDLINE | ID: mdl-35473780
Interleukin-1 (IL-1) blockade is an anti-inflammatory treatment that may affect exercise capacity in heart failure (HF). We evaluated patient-reported perceptions of exertion and dyspnea at submaximal exercise during cardiopulmonary exercise testing (CPET) in a double-blind, placebo-controlled, randomized clinical trial of IL-1 blockade in patients with systolic HF (REDHART [Recently Decompensated Heart Failure Anakinra Response Trial]). Patients underwent maximal CPET at baseline, 2, 4, and 12 weeks and rated their perceived level of exertion (RPE, on a scale from 6 to 20) and dyspnea on exertion (DOE, on a scale from 0 to 10) every 3 minutes throughout exercise. Patients also answered 2 questionnaires to assess HF-related quality of life: the Duke Activity Status Index and the Minnesota Living with Heart Failure Questionnaire. From baseline to the 12-week follow-up, IL-1 blockade significantly reduced RPE and DOE at 3- and 6-minutes during CPET without changing values for heart rate, oxygen consumption, and cardiac workload at 3- and 6-minutes. Linear regression identified 6-minute RPE to be a strong independent predictor of both physical symptoms (Minnesota Living with Heart Failure Questionnaire; ß = 0.474, p = 0.002) and perceived exercise capacity (Duke Activity Status Index; ß = -0.443, p = 0.008). In conclusion, patient perceptions of exertion and dyspnea at submaximal exercise may be valuable surrogates for quality of life and markers of response to IL-1 blockade in patients with HF.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-1 / Dispneia / Esforço Físico / Insuficiência Cardíaca Sistólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Interleucina-1 / Dispneia / Esforço Físico / Insuficiência Cardíaca Sistólica Tipo de estudo: Clinical_trials / Diagnostic_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article